** Cancer drug developer’s shares up as much as 53.16 pct to $2.67 - biggest intraday pct gain in more than 3 months
** Says an independent data monitoring committee (IMDC) recommended co to continue its late-stage study of its lead drug, rigosertib, in patients with higher-risk myelodysplastic syndromes
** IMDC recommends co to increase enrollment by adding 135 patients to the original target to reach a total enrollment of 360 patients
** Myelodysplastic syndromes are a group of cancers in which immature blood cells in the bone marrow do not mature or become healthy blood cells
** In 2014, rigosertib failed to improve overall survival in late-stage trial in high risk myelodysplastic syndrome patients
** Up to Tuesday’s close, stock had fallen about 36 pct in the past twelve months (Reporting by Akankshita Mukhopadhyay in Bengaluru)
 